Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to HK Equities

HK Equities · Finance research note

HKEX 0867 - China Medical System Holdings Ltd.

Research and analysis only
View analysis Browse HK Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* -0.70%
Risk / Std Dev (Ann.)* 37.24%
1-Year Price Return* -7.05%

Latest Market Data (as of 2026-08-14, Hong Kong time):

Metric Value
Last Price HK$11.82
52-Week Range HK$9.51 – HK$15.63
Observation Count 245 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year price series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in HK$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2025 FY2024
Revenue Reported revenue HK$8.21B HK$7.47B
Net income Reported net income HK$1.49B HK$1.62B
Total assets Year-end reported balance HK$19.20B HK$18.05B
Shareholders’ equity Year-end reported balance HK$17.40B HK$16.31B
Net margin Net income ÷ revenue 18.13% 21.69%
Asset turnover Revenue ÷ total assets 0.4277x 0.4138x
Equity multiplier Total assets ÷ shareholders’ equity 1.1037x 1.1064x
ROE Net margin × asset turnover × equity multiplier 8.56% 9.93%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue HK$8.21B
Prior annual revenue HK$7.47B
EBIT HK$2.12B
Tax rate 31.37%
NOPAT = EBIT × (1 − tax rate) HK$1.46B
Forecast start-growth basis 9.95%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT HK$1.46B
Add: depreciation & amortisation HK$266.93M
Less: capital expenditure -HK$514.41M
Less/(add): working-capital cash-flow movement -HK$648.78M
Current unlevered FCFF HK$560.94M

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 9.95% HK$1.60B HK$293.48M -HK$565.59M -HK$713.33M HK$616.75M HK$586.55M
2 8.09% HK$1.73B HK$317.22M -HK$537.80M -HK$771.01M HK$740.15M HK$636.65M
3 6.22% HK$1.84B HK$336.96M -HK$493.17M -HK$819.00M HK$864.32M HK$672.43M
4 4.36% HK$1.92B HK$351.66M -HK$433.17M -HK$854.73M HK$983.53M HK$692.07M
5 2.50% HK$1.97B HK$360.45M -HK$360.45M -HK$876.10M HK$1.09B HK$694.77M

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 1.10
Cost of equity 10.77%
Pre-tax cost of debt 2.62%
WACC 10.56%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value HK$13.88B
Implied terminal EV / EBITDA 4.30x
Terminal value as % of enterprise value 71.90%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF HK$3.28B
Present value of terminal value HK$8.40B
Indicated enterprise value HK$11.68B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value HK$11.68B
Less: gross interest-bearing debt HK$690.08M
Add: cash and equivalents HK$5.79B
Add: affiliate investments HK$0.00
Less: minority interests HK$147.03M
Indicated common equity value HK$16.63B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 2,433,131,512.00
Share-count basis reported shares outstanding; option/RSU dilution data not separately available
Current market price HK$11.74
DCF indicative value per share HK$6.84
Indicative value vs. market price -41.78%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 3/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 16:38:35.835189 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set Asia Pacific ex Japan
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-20 to 2026-06-30
Aligned daily observations 210
Minimum observation requirement 120
Currency conversion for HK listings HKD adjusted close divided by daily USD/HKD close before simple daily return calculation

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -32.41% -33.01%
Adjusted R² 0.04 0.04
Annualised residual volatility 34.96% 34.80%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.68 (3.40) 0.76 (3.56)
Size (SMB) -0.05 (-0.16) 0.15 (0.42)
Value (HML) 0.39 (1.42) 0.24 (0.77)
Profitability (RMW) NM -0.27 (-0.70)
Investment (CMA) NM 0.49 (1.12)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

hkexstockequity867